Published in Cancer Immunol Immunother on May 20, 2015
Immunotherapy for opportunistic infections: Current status and future perspectives. Virulence (2016) 0.82
The next step toward GMP-grade production of engineered immune cells. Oncoimmunology (2015) 0.75
Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA. Oncoimmunology (2016) 0.75
Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J Immunother Cancer (2016) 0.75
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (1999) 11.04
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
The biology of human natural killer-cell subsets. Trends Immunol (2001) 10.10
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
Immunotherapy through TCR gene transfer. Nat Immunol (2001) 2.41
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 2.07
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A (2006) 1.88
Treating cancer with genetically engineered T cells. Trends Biotechnol (2011) 1.83
NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood (2005) 1.78
Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol (2009) 1.76
Re-engineering the European Union Clinical Trials Directive. Lancet (2012) 1.71
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood (2012) 1.68
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood (2014) 1.64
γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs. Blood (2012) 1.62
HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders. Blood (2014) 1.51
Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS One (2008) 1.47
Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol (2000) 1.33
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2014) 1.29
NKG2D ligands as therapeutic targets. Cancer Immun (2013) 1.26
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol (2010) 1.20
Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Res (2011) 1.05
Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Immunol Rev (2014) 1.04
Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor. Blood (2011) 1.03
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
Requirements for effective antitumor responses of TCR transduced T cells. J Immunol (2008) 1.02
The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol (2013) 0.94
Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther (2012) 0.94
Negative depletion of CD3(+) and TcRαβ(+) T cells. Curr Opin Hematol (2012) 0.93
Human Vgamma9Vdelta2 T cells: from signals to functions. Semin Immunol (2010) 0.92
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87
Hunting for clinical translation with innate-like immune cells and their receptors. Leukemia (2013) 0.86
Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol (2013) 0.84
Targeted activation of human Vγ9Vδ2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease. Cancer Cell (2014) 0.83
Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL. Bone Marrow Transplant (2013) 0.82
Cancer Immunotherapy Using γδT Cells: Dealing with Diversity. Front Immunol (2014) 0.82
Gene and cell therapy funding opportunities in horizon 2020: an overview for 2014-2015. Hum Gene Ther (2014) 0.77
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood (2012) 2.57
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Response definition criteria for ELISPOT assays revisited. Cancer Immunol Immunother (2010) 2.20
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs. Blood (2012) 1.62
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood (2011) 1.50
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol (2006) 1.41
Influence of donor cytomegalovirus (CMV) status on severity of viral reactivation after allogeneic stem cell transplantation in CMV-seropositive recipients. Clin Infect Dis (2011) 1.40
A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol (2011) 1.38
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res (2010) 1.38
Meeting Report from the Second "Minimum Information for Biological and Biomedical Investigations" (MIBBI) workshop. Stand Genomic Sci (2010) 1.35
Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput Biol (2013) 1.35
Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. J Immunol (2008) 1.28
The impact of harmonization on ELISPOT assay performance. Methods Mol Biol (2012) 1.18
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood (2006) 1.18
Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene (2004) 1.14
Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol (2008) 1.12
A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A (2013) 1.11
Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. Biol Blood Marrow Transplant (2009) 1.08
Current insights into ocular graft-versus-host disease. Curr Opin Ophthalmol (2010) 1.07
Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol (2012) 1.05
Harmonization of the intracellular cytokine staining assay. Cancer Immunol Immunother (2012) 1.05
Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother (2004) 1.04
Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor. Blood (2011) 1.03
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol Immunother (2004) 1.03
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med (2011) 1.02
Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. Cytometry A (2008) 0.99
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother (2015) 0.99
T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies. Expert Opin Biol Ther (2010) 0.99
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol Immunother (2012) 0.98
Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. Immunol Res (2006) 0.97
Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood (2006) 0.95
Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2-11-mediated immune evasion. J Gen Virol (2007) 0.91
A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. J Transl Med (2011) 0.90
Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors. Expert Opin Biol Ther (2009) 0.90
Cytomegalovirus interleukin-10 expression in infected cells does not impair MHC class I restricted peptide presentation on bystanding antigen-presenting cells. Viral Immunol (2006) 0.90
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87
A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood (2007) 0.86
The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunol Immunother (2012) 0.86
Designing TCR for cancer immunotherapy. Methods Mol Med (2005) 0.85
Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunol Immunother (2014) 0.85
Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Mol Immunol (2008) 0.83
Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. Cancer Immunol Immunother (2015) 0.83
Successive immunoglobulin and cytokine expression in the small intestine of juvenile chicken. Dev Comp Immunol (2010) 0.83
The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study. Haematologica (2011) 0.83
Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother (2005) 0.82
Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells. Blood (2010) 0.82
Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells. Cytometry A (2014) 0.81
Rapid molecular dissection of viral and bacterial immunomes. Eur J Immunol (2006) 0.80
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity. BMC Cancer (2011) 0.79
Structured reporting of T cell assay results. Cancer Immun (2013) 0.77
Multifunctional γδ T cells and their receptors for targeted anticancer immunotherapy. Oncoimmunology (2013) 0.76
Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring. Oncoimmunology (2012) 0.76
Nitric oxide promotes resistance to tumor suppression by CTLs. J Immunol (2006) 0.76
Rapid identification of an HLA-B*1501-restricted vaccinia peptide antigen. Vaccine (2007) 0.76
Report on the sixth annual meeting of the Association for Immunotherapy of Cancer (CIMT), May 15 and 16, 2008 in Mainz, Germany. Cancer Immunol Immunother (2008) 0.75
CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancer. June 3-5, Mainz, Germany. Cancer Immunol Immunother (2009) 0.75
Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25-27, 2011, Mainz, Germany. Cancer Immunol Immunother (2011) 0.75
Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction. Cancer Immunol Immunother (2014) 0.75
Toward next-generation cancer immunotherapy: 10th annual meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 23-25, 2012. Cancer Immunol Immunother (2013) 0.75
Report on the Fifth Annual Meeting of the Association for Immunotherapy of Cancer (CIMT) April 12-14, 2007 in Würzburg, Germany. Cancer Immunol Immunother (2007) 0.75
Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013. Cancer Immunol Immunother (2013) 0.75
Correction: Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody. J Immunol (2017) 0.75
Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014. Cancer Immunol Immunother (2014) 0.75
CIMT 2010: report on the eighth annual meeting of the Association for Cancer Immunotherapy, May 26-28, 2010, Mainz, Germany. Cancer Immunol Immunother (2010) 0.75